Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients

doi:10.5306/wjco.v12.i10.947

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5553)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

253

WORD

202

HTML

1943

Figures (1-3)

239

Tables (1-5)

265

Sum=2902

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

295

Download

883

Sum=1178

Publishing Process of This Article

Item

Count

Browse

463

Download

1010

Sum=1473

Oct 24, 2021 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Oncol. Oct 24, 2021; 12(10): 947-959
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.947

Table 2 Concentrations of molecular markers of recruited subjects of glioma patients in terms of isocitrate dehydrogenase mutant and wildtype glioma

No.	Factors	Controls (n = 45)	IDH-mutant (n = 60)	IDH-wildtype (n = 30)	P value
1	KYN (ng/mL)	5.009 (0.052-34.43)	77.155 (1.56-387.44)	237.318 (53.43-894.95)	< 0.0001^c
2	IL-6 (pg/mL)	37.009 (6.715-62.49)	68.62 (21.85-209.73)	197.672 (59.217-803.711)	< 0.0001^c
3	NLR	1.59 (0.87-2.8)	3.67 (1.23-11.5)	5.585 (3.1-18)	0.0002^c
4	TIMP-1 (ng/mL)	38.03 (10.26-73.99)	82.54 (25.09-131.30)	107.01 (37.175-185.09)	0.0405^a
5	hTERT (ng/mL)	1.029 (0.075-1.58)	1.364 (0.1-6.886)	2.185 (0.565-8.84)	< 0.0001^c

^aP < 0.05.

^cP < 0.001.

Median with ranges of all circulatory markers in controls, isocitrate dehydrogenase (IDH)-m and IDH-w. KYN: Kynurenine; IL-6: Interleukin-6; NLR: Neutrophil-lymphocytes ratio; TIMP-1: Tissue inhibitor metalloproteases-1; hTERT: Human telomerase reverse transcriptase; IDH: Isocitrate dehydrogenase.

Citation: Gandhi P, Shrivastava R, Garg N, Sorte SK. Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients . World J Clin Oncol 2021; 12(10): 947-959
URL: https://www.wjgnet.com/2218-4333/full/v12/i10/947.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i10.947